Clinical Trial Update: SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) [Phase 3]

View source ↗

Summary

Phase 3 trial SIGMA is investigating safusidenib as maintenance therapy for IDH1-mutant glioma and related astrocytoma/oligodendroglioma subtypes; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Idh-mutant
• Glioma
• Idh1-mutant Glioma
• Oligodendroglioma
• Oligodendroglioma Idh-mutant and 1p 19q-codeleted

Drugs mentioned

• Safusidenib (safusidenib)

Snippet

Sponsor: Nuvation Bio Inc. | Conditions: Glioma, Astrocytoma, Grade IV | Phase 3 | Status: RECRUITING